Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,615 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis.
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K. Uzawa A, et al. Among authors: ozawa y. Neurotherapeutics. 2023 Mar;20(2):518-523. doi: 10.1007/s13311-022-01335-3. Epub 2023 Jan 6. Neurotherapeutics. 2023. PMID: 36607596 Free PMC article.
Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis.
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K. Uzawa A, et al. Among authors: ozawa y. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):467-473. doi: 10.1136/jnnp-2022-330519. Epub 2023 Jan 24. J Neurol Neurosurg Psychiatry. 2023. PMID: 36693723
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan.
Yasuda M, Uzawa A, Kuwabara S, Suzuki S, Akamine H, Onishi Y, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K. Yasuda M, et al. Among authors: ozawa y. J Neuroimmunol. 2023 Dec 15;385:578241. doi: 10.1016/j.jneuroim.2023.578241. Epub 2023 Nov 7. J Neuroimmunol. 2023. PMID: 37952282
Two onset types of achalasia and the long-term course to diagnosis.
Kurosugi A, Matsumura T, Sonoda M, Kaneko T, Takahashi S, Okimoto K, Akizue N, Ohyama Y, Mamiya Y, Nakazawa H, Horio R, Goto C, Ohta Y, Taida T, Kikuchi A, Fujie M, Murakami K, Uesato M, Ozawa Y, Kato J, Matsubara H, Kato N. Kurosugi A, et al. Among authors: ozawa y. Esophagus. 2024 Jun 6. doi: 10.1007/s10388-024-01069-5. Online ahead of print. Esophagus. 2024. PMID: 38844704
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).
Kobayashi K, Ogasawara S, Itobayashi E, Okubo T, Itokawa N, Nakamura K, Moriguchi M, Watanabe S, Ikeda M, Kuroda H, Kawaoka T, Hiraoka A, Yasui Y, Kuzuya T, Sato R, Kanzaki H, Koroki K, Inoue M, Nakamura M, Kiyono S, Kanogawa N, Kondo T, Nakamoto S, Ozawa Y, Tsuchiya K, Atsukawa M, Aikata H, Aramaki T, Oka S, Morimoto N, Kurosaki M, Itoh Y, Izumi N, Kato N. Kobayashi K, et al. Among authors: ozawa y. Invest New Drugs. 2024 Jun 6. doi: 10.1007/s10637-024-01441-3. Online ahead of print. Invest New Drugs. 2024. PMID: 38842657
1,615 results